Skip to Content
MilliporeSigma
All Photos(1)

Documents

G0776

Sigma-Aldrich

Disialoganglioside-GD2 from bovine brain

~95%, lyophilized powder, semisynthetic

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
65988-71-8
MDL number:
MFCD00131133
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

200

Assay

~95%

form

lyophilized powder

storage temp.

−20°C

InChI

1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)/b32-30+/t43?,44?,45-,46-,47?,48?,49-,50-,51-,53+,54+,55-,56?,57?,58+,59-,60-,61-,62-,63-,64+,65+,66+,67-,68+,69-,70+,73-,74+/m1/s1

InChI key

FFILOTSTFMXQJC-QCFYAKGBSA-N

Amino Acid Sequence

Cer-Glc-Gal(NeuAc-NeuAc)-GalNAc

General description

Disialoganglioside GD2 is a cell surface-associated glycosphingolipid, which comprises sialic acid moiety and is regarded as a carbohydrate antigen.. It is expressed in the skin melanocytes, central and peripheral nervous system.
Gangliosides are major constituents of neuronal cell membranes and endoplasmic reticulum; contain a sialated polysaccharide chain linked to ceramide through a β-glycosidic linkage; for classification of gangliosides see Svennerholm, L., et al. (eds.), Structure and Function of Gangliosides, New York, Plenum, 1980.

Application

Disialoganglioside-GD2 from bovine brain has been used:
  • in the ganglioside- enzyme-linked immunosorbent assay (ELISA)
  • in capture ELISA with anti-GD2 antibody (ch14.18)
  • as a control to test its effect on reactivating autophagy in primary fibroblasts

Biochem/physiol Actions

Disialoganglioside GD2 is expressed in neuroblastoma, melanoma and small cell lung cancer. It is an immunotherapeutic target and is also regarded as a tumor-associated antigen. GD2 may favor cell migrationin tumors by promoting cell growth, as well as extracellular matrix component attachment.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gopalan Soman et al.
Journal of immunological methods, 373(1-2), 181-191 (2011-09-07)
Two assay methods for quantification of the disialoganglioside (GD2)-specific binding activities of anti-GD2 monoclonal antibodies and antibody immunofusion proteins, such as ch14.18 and hu14.18-IL2, were developed. The methods differed in the use of either microtiter plates coated with purified GD2
Nina Eissler et al.
Cancer research, 72(16), 3958-3966 (2012-06-30)
A major goal of tumor immunotherapy is the induction of long-lasting systemic T-cell immunity. Bispecific antibodies (bsAbs) that lack the immunoglobulin Fc region confer T-cell-mediated killing of tumor cells but do not induce long-term memory. In contrast, trifunctional bsAbs comprise
Angelika B Riemer et al.
European journal of immunology, 36(5), 1267-1274 (2006-03-29)
The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastoma, sarcoma and small cell lung cancer. Due to its specific expression on tumor surfaces, GD2 is an attractive target for immunotherapies. The mouse/human
Anastasia Shibina et al.
Journal of molecular medicine (Berlin, Germany), 91(4), 459-472 (2012-10-12)
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-retinoic acid for post-myeloablative maintenance therapy increased survival in high-risk NB, but the overall prognosis
Fariba Navid et al.
Current cancer drug targets, 10(2), 200-209 (2010-03-06)
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service